A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy
and safety of PRAX-114 in participants with moderate to severe major depressive disorder
(MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo
in a 1:1 ratio.